Literature DB >> 8883953

Inducible gene expression from defective herpes simplex virus vectors using the tetracycline-responsive promoter system.

D Y Ho1, J R McLaughlin, R M Sapolsky.   

Abstract

Herpes simplex virus-based amplicon vectors have been used for gene transfer into cultured neurons and the adult CNS. Since constitutive expression of a foreign gene or overexpression of an endogenous gene may have deleterious effects, the ability to control temporal expression would be advantageous. To achieve inducible gene expression, we have incorporated the tetracycline-responsive promoter system into amplicon vectors and showed, both in vitro and in vivo, that expression can be modulated by tetracycline. Using the firefly luciferase as the reporter gene, maximal repression by tetracycline in hippocampal cultures was about 50-fold. Withdrawal of tetracycline derepressed gene expression, reaching maximal levels within 10-12 h. In contrast, addition of tetracycline to cultures without prior tetracycline exposure inhibited gene expression rapidly; luciferase activity was reduced to less than 8% within 24 h. In adult rat hippocampus, vectors expressing luciferase or the Escherichia coli lacZ were repressed by tetracycline 9- and 60-fold, respectively. Maximum gene expression from the vectors occurred 2-3 days post-infection and declined thereafter. Such decline impeded further induction of expression by withdrawing tetracycline. This study demonstrates the feasibility of incorporating a powerful inducible promoter system into HSV vectors. The development of such an inducible viral vector system for gene transfer into the adult CNS might prove to be of experimental and therapeutic value.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8883953     DOI: 10.1016/0169-328x(96)00097-6

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  8 in total

Review 1.  Regulatable systems: applications in gene therapy and replicating viruses.

Authors:  S Agha-Mohammadi; M T Lotze
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 2.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 3.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

Review 4.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

5.  Neuroprotective potential of a viral vector system induced by a neurological insult.

Authors:  C R Ozawa; J J Ho; D J Tsai; D Y Ho; R M Sapolsky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

6.  General strategy for constructing large HSV-1 plasmid vectors that co-express multiple genes.

Authors:  X Wang; G R Zhang; M Sun; A I Geller
Journal:  Biotechniques       Date:  2001-07       Impact factor: 1.993

7.  Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease.

Authors:  O Corti; A Sánchez-Capelo; P Colin; N Hanoun; M Hamon; J Mallet
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

8.  Long-term inducible expression in striatal neurons from helper virus-free HSV-1 vectors that contain the tetracycline-inducible promoter system.

Authors:  Qingshen Gao; Mei Sun; Xiaodan Wang; Guo-Rong Zhang; Alfred I Geller
Journal:  Brain Res       Date:  2006-03-20       Impact factor: 3.252

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.